ClinicalTrials.gg
Not yet recruitingNCT07914738Updated Nov 4, 2026

A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)

A Phase 1 interventional study of LY3819469 in Lipoprotein(a), sponsored by Eli Lilly and Company. Not yet recruiting. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Updated Nov 4, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The main purpose of this study will evaluate how the body takes in lepodisiran (LY3819469) after a single injection under the skin. Researchers will compare how much lepodisiran gets into the body from each injection site. The study will also look at how safe lepodisiran is and how it affects lipoprotein(a) (Lp(a)), in healthy adults who have high Lp(a) levels. Participants will take part in the study for about 17 weeks.

Participants will be admitted to the clinical research unit on Day -1 and remain confined until discharge on Day 4. The study drug will be administered on Day 1. Participants will return to the clinical research unit for outpatient visits on Days 8, 15, 29, and 57.

02

Conditions studied

  • Lipoprotein(a)
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 (21 for the Singapore site) to 70 years of age, inclusive, at the time of signing the ICF.
  • Are overtly healthy as determined by medical evaluation including medical history, physical examination and other screening procedures.
  • Have Lp(a) levels greater than or equal to (≥)75 nanomole per liter (nmol/L) as measured by the central laboratory.
  • Have, except for Lp(a) and lipid panel, clinical laboratory test results within normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not by the investigator.
  • Have a within the range of 18.5 to 35.0 kilograms per square meter (kg/m²), inclusive, at the time of screening.
  • Are individuals assigned male at birth (AMAB) or assigned female at birth (AFAB).

Exclusion criteria

Exclusion Criteria:

  • Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, dermatological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs.
  • Have had any history of clinically overt cardiovascular disease (CVD).
  • Have known allergies to lepodisiran, related compounds, or any components of the formulation.
  • Have a history of multiple or severe allergic reactions or a history of severe anaphylactic reaction.
  • Have multiple or severe drug allergies.
  • Have a history or presence of psychiatric disorders.
  • Have participated, within the last 1 month, in a clinical study involving an product.
  • Have previously completed or withdrawn from this study or any other study investigating an Lp(a) small interfering ribonucleic acid (RNA) therapeutic within 1 year prior to screening.
  • Have an estimated less than (\<)60 milliliter per minute per 1.73 square meters (mL/min/1.73 m²).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    LY3819469 (Upper Arm)

    Administered subcutaneously (SC) in the upper arm

    Drug: LY3819469

  • Experimental
    LY3819469 (Thigh)

    Administered SC in the thigh

    Drug: LY3819469

  • Experimental
    LY3819469 (Abdomen)

    Administered SC in the abdomen

    Drug: LY3819469

Interventions

  • Administered SC

    Also known as: Lepodisiran

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of LY3819469

    Time frame: Day 1 through Day 15

  2. PK: Area Under the Concentration versus Time Curve (AUC) of LY3819469

    Time frame: Day 1 through Day 15

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2026
First posted
Nov 4, 2026
StartEst.
Nov 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07914738
Responsible party
Sponsor
First posted
Nov 4, 2026
Start date
Nov 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lepodisiran

Start the discussion